Faceplant

ZUCK

Dispatch from the Aftermath of the Facebook IPO

In the days before the Facebook hysteria had fully bloomed, we sought comment from investors who planned to buy the stock. Did they know half of Twitter was bashing Facebook as massively overpriced? Were they chasing the next Google? Did they just like Zuck?

Yesterday we finally caught up with a Facebook investor. Alper Aydinoglu Read More

Morning Read

This courtoom drawing shows Assistant US

Gupta Insider Trading Trial Starts with Cliches, Morgan Stanley’s Facebook Projections: Wall Street Roundup

Another big insider trading trial kicks off, a Morgan Stanley analyst cut Facebook projections ahead of Friday’s IPO and the day’s dose on JPMorgan trading losses. And still more in today’s Wall Street roundup.

What’s Good for the Gupta: The trial of former McKinsey & Co. chief executive Rajat Gupta opened yesterday, and legal Read More

Morning Read

Borrelia burgdorferi, the causative agent for Lyme disease. Credit: Centers for Disease Control and Prevention.

JPMorgan’s Rocky Relations, Facebook’s Slow Open and the Next Big Thing in Insider Trading; Wall Street Roundup

A bug in JPMorgan’s chief investment office led to discord. A glitch in Nasdaq’s system delayed Facebook’s IPO. The next big insider trading trial opens today. And more, in today’s Wall Street roundup.

Down-tick: The London and New York desks of JPMorgan’s chief investment office had long been at odds, and shouting matches were common Read More

Morning Read

JP Morgan Chase Headquarters in New York

JPMorgan Loses Another $1 Billion on Bad Bet, Facebook Brokers Say They’re Out of Stock: Wall Street Roundup

Losses mount: Tack on another $1 billion to the $2 billion-plus in trading losses JPMorgan disclosed a week ago today, says Dealbook, as hedge funds and other investors—knowing that Jamie Dimon’s firm is under pressure to sell out from under the losing bet—continue to prey on the firm’s huge, illiquid position.

Before Bruno Iksil Read More